chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Had slurred speech; Cannot put thoughts into words; Tingling in her arms and legs/ tingling in her left arm that she got the vaccine; Her foot went numb; Had fast, heavy breathing; Almost like a panic attack; This is a spontaneous report received from a contactable reporter(s) (Pharmacist) from medical information team for a Pfizer sponsored program.  A 52 year-old female patient received bnt162b2 (BNT162B2), administered in deltoid left, administration date 04Aug2021 (Lot number: FC3180, Expiration Date: Sep2021) at the age of 52 years as dose 1, 0.3 ml single for covid-19 immunisation. Relevant medical history included: "Thyroid condition" (ongoing). Concomitant medication(s) included: LEVOTHYROXINE taken for thyroid disorder (ongoing). The following information was reported: PARAESTHESIA (non-serious) with onset 04Aug2021, outcome "not recovered", described as "Tingling in her arms and legs/ tingling in her left arm that she got the vaccine"; HYPOAESTHESIA (non-serious) with onset 04Aug2021, outcome "recovered" (05Aug2021), described as "Her foot went numb"; RESPIRATION ABNORMAL (non-serious) with onset 04Aug2021, outcome "recovered" (05Aug2021), described as "Had fast, heavy breathing"; PANIC ATTACK (non-serious) with onset 04Aug2021, outcome "recovered" (05Aug2021), described as "Almost like a panic attack"; DYSARTHRIA (non-serious) with onset 05Aug2021, outcome "not recovered", described as "Had slurred speech"; APHASIA (non-serious) with onset 05Aug2021, outcome "unknown", described as "Cannot put thoughts into words". Therapeutic measures were not taken as a result of paraesthesia, hypoaesthesia, respiration abnormal, panic attack, dysarthria, aphasia. No follow-up attempts are possible. No further information is expected.
Pt visited ED for "tightening in throat".  Treated with antibiotics for pharyngitis.  Soldier doing well. Given amoxicillin.
This spontaneous report as received from a consumer refers to a 12 year old female patient. The patient has none medical history or drug reactions. On an unspecified date in November 2015, the patient was vaccinated with the second dose of GARDASIL (Dosage, route of administration, lot # and expiration date were not reported), additionally it was stated that the patient received GARDASIL with the wrong gauge needle. It was also reported that there was no specific information on the first or third dose of GARDASIL. No other suspect or concomitants therapies were reported. On the same date (reported as within "a couple of hours of administration"), the patient's arm was sore. Additionally, it was reported that an unspecified treatment was given for sore arm, that no laboratory diagnostics were performed, that the patient did not sought medical attention and also was stated that the patient was not hospitalized. No product quality complaint was involved. At the time of the report, the outcome of sore arm was reported as recovered. The relatedness between sore arm and GARDASIL was not reported. Additional information has been requested. Additional information has been requested.
This case was reported by a nurse and described the occurrence of expired vaccine used in a 21-year-old male patient who received HAVRIX (batch number AHAVB597AA, expiry date 6th September 2014). On 16th September 2014, the patient received HAVRIX. On an unknown date, an unknown time after receiving HAVRIX, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown. It was unknown if the reporter considered the expired vaccine used to be related to HAVRIX. Additional information received: On 16 September 2014, 21 years old patient who received an expired vaccine (06 September 2014).
This spontaneous report as received from a 61 year old female consumer referring to herself with a history of receiving a "flu shot about 20 years ago and it made her fall to the floor". The patient's concurrent conditions and concomitant medication were not reported. On 15-MAY-2017, the patient was vaccinated with ZOSTAVAX "1 time vaccine" (dose, route of administration, site of administration, lot number and expiration date were not reported) for prophylaxis. On 29-MAY-2017, the patient experienced a rash all over her chest and arm (NOS) that was itchy and hurt. The patient was taking prednisone 40 to 60 mg and cortisone cream 1%. The patient reported that the rash was clearing up but was experiencing vomiting and diarrhoea. In JUL-2017, reported as "this last Sunday", the patient broke out all over again and had terrible chills and fever. The patient reported the rash look like diamond patterns and round circles. The patient reported that she was going to use cortisone cream, about 2.5%. The patient also reported that she uses her inhaler and nebulizer treatments several times since she got the vaccine. The patient reported that she has no pets. The outcome of rash, fever, diarrhoea and vomiting was unknown. Causality assessment was not reported. No further information was provided. Additional information has been requested.
Patient called two hours after receiving Shingrix and stated she was having difficulty moving her arm.  She followed up with her PCP who prescribed lidocaine cream to help with pain.  It was too expensive so she used the OTC version of lidocaine.
Pt s/p vaccine on 3/23/2021. Began w/ back pain on 3/25-3/26/2021 and was noted to have progression even after 4/21 vaccine. S/p MRI c/w lumbar discitis/osteomyeltis and bx negative. On empiric abx. Thought to be related to prior fall possibly but with vaccine 48 hrs prior to back pain development will submit. No cultures were ever positive.
Arm Sore and a little tired. Got Pneumonia in June and came back in October.
Proquad given right thigh 4/9/07 cellulitis developed 4/10/07 office visit 4/11/07 IM Rocephin 1 gram po Augmentin to began 4/12/07 am
Initial report received from a healthcare professional on 06 August 2012. A female patient whose medical history included no illness at the time of vaccination, and had no known allergies and whose concomitant medications were not reported, had received second dose of IMOVAX rabies Sanofi Pasteur Ltd. (lot number not reported) in the left deltoid on an unspecified date. The patient's receiving per exposure rabies vaccination; first dose 7 days before second dose. On an unspecified date, the patient developed redness, warmth and induration at the site of vaccination. Corrective medications and laboratory investigations were not reported. The patient's outcome was recovered on unspecified date. List of documents held by sender: None. Follow-up information was received on 16 November 2012. The patient's concomitant medications included ORTHO TRI-CYCLEN, CELEXA, UNISOM, AND AMBIEN. The patient had received Dose 1 of IMOVAX rabies vaccine on 10 July 2012 (lot number G1109-2) intramuscularly in left deltoid. On 17 July 2012, the patient received dose 2 of IMOVAX rabies vaccine intramuscularly in left deltoid (lot number G1109-2, site left). The patient had received dose 3 of IMOVAX Rabies vaccine on 07 August 2012 (lot number G1109-2) intramuscularly in right deltoid. On 10 July 2012, the patient had received subcutaneous IPOL (lot number H1330, site left), Sanofi Pasteur ltd, TYPHIM V vaccine on right deltoid intramuscularly (lot number : G1130), Yellow fever vaccine subcutaneously (lot number UH348AA, site right) and MENVEO vaccine (manufacturer Novartis, lot number M11073) intramuscularly on right deltoid.
Extreme swelling in spot of vaccinations. High fever. Constant crying. Within 2 weeks, stopped speaking, interacting, and made no eye contact. She sat and rubbed a blanket on her face all day and wouldn't eat to communicate. She started receiving speech, occupational, and developmental therapy. We also started her on chelation therapy.
This is a spontaneous report from a contactable consumer (patient) or other non-healthcare professional received from a Pfizer colleague.   A 55-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number and Expiration date was not reported), via an unspecified route of administration on an unspecified date as a dose 1, single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. It was reported that, the patient got Covid after receiving first Pfizer vaccine shot and experienced symptoms of sinus, headache, sore throat, and muscle ache on an unspecified date. Seemed like bad sinus infection. The events took place after use of product. On an unspecified date, the patient underwent lab tests and procedures which included Covid (SARS-CoV-2 test), resulted as got Covid after receiving first Pfizer vaccine shot. The outcome of the events was unknown.  No follow-up attempts are possible, information about lot/batch number cannot be obtained. No further information is expected.
Two days fever, chills, headache, body aches; seems like adverse events are starting to get less
Day after second dose presented with sever muscle pain in vaccination arm; Pain is felt deep in muscle and radiates from injection site to elbow; Pain is felt deep in muscle and radiates from injection site to elbow; Severe muscle pain in vaccination arm; This is a spontaneous report from a contactable healthcare professional, the patient. A 67-year-old non-pregnant female patient received second dose of BNT162b2 (COMIRNATY; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 19Jun2021 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Information on concomitant medications were not available (N/A). The patient previously received the first dose (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8735) via an unspecified route of administration in the left arm on 29May2021 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. On 20Jun2021, the day after second dose, the patient presented with severe muscle pain in vaccination arm. Pain was felt deep in muscle and radiates from injection site to elbow side effect/adverse event was ongoing and presented when arm was lifted in any direction. She also reported that to do any task assistance from right arm is required. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the reported events. The clinical outcome of the events severe muscle pain in vaccination arm, pain was felt deep in muscle and radiates from injection site to elbow and day after second dose presented with sever muscle pain in vaccination arm were not resolved at the time of this report.  The lot number for BNT162b2 was not provided and will be requested during follow up.
Became lightheaded, fell backwards and caught by mom. Placed on exam table where she became diaphoretic, pale, BP decrease 50/36, HR 40. Given fluids, Recovered after 15 minutes, Hct 13.5, VS stable after 1/2 hr.
felt horrible; she was going to pass out; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A female patient received pneumococcal 20-val conj vac (dipht CRM197 protein) (PREVNAR 20), on 10Nov2022 as dose number unknown, single (Batch/Lot number: unknown) for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: FEELING ABNORMAL (non-serious), outcome "unknown", described as "felt horrible"; DIZZINESS (non-serious), outcome "unknown", described as "she was going to pass out".   Additional information: Caller was "injected with" Prevnar 20 on 10Nov2022 and the next am she felt horrible like she was going to pass out and she wants to know if this is a side effect of the product. As warm transfer was completed, the line remained connected, however the caller did not speak on the other end to confirm or deny connection.  The information on the batch/lot number for pneumococcal 20-val conj vac (dipht CRM197 protein) has been requested and will be submitted if and when received.
Moderna COVID-19 Vaccine EUA: About 15 minutes after receiving the vaccine, the vaccine recipient experienced dizziness and lightheadedness. They refused to go to the ED.
Profound body aches, chills, headache Began with pain at injection site around 2pm; by 7pm I couldn't stand up; used ibuprophen with no effect; took tylenol at 10pm to reduce pain enough that I could sleep. Aches persisting at lower level the following day
Flu shot 11/04/2003.  Today temperature 100.3, congestion, cold increased left arm, reddened, hard, hot to touch (left arm).  According to mom, no reaction last night when bathed.  11/07/2003: MD from mom analisc's arm, swelling decreased not as hot to touch."
Vaccine @ 1017. 1019 when walking to chair became light headed and dizzy. 1022 vision started getting blurry. 1024 started with a tension HA reports she has these frequently but did not arrive with a HA.B/P 112/64, P-86, R-18, 02 sat 98% ra. 1034 Pt report dizziness resolved but vision cont to be blurry. 02 sat 99% ra, HR-80. 1051 Pt report vision is getting better . b/p 110/62,hr-89, 02sat 99% ra, r-18. 1056 Reports vision better and all other issues have resolved. Pt instructed to f/u with MD as needed and eat prior to next covid vaccine.
Several severe AFib attacks and had to have a pacemaker put in after my heart stopped.  Then dealt with cardiac tamponade a month later and then as an ablation and watchman put in.  AFib unlike previously always was fairly infrequent and easily controlled.  Also nodules on my lungs from renal cancer have been stable since 2017 and my cat scan after the above events showed they had started to grow
Covid - AG + test 18Jan; Covid - AG + test 18Jan; This is a spontaneous report received from a contactable reporter(s) (Nurse).  A 50-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 27Oct2022 as dose 4 (booster), single (Lot number: gj6742) at the age of 49 years intramuscular, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 18Jan2023, outcome "recovering" and all described as "Covid - AG + test 18Jan". The patient underwent the following laboratory tests and procedures: Nasopharyngeal swab: (18Jan2023) Positive. Therapeutic measures were not taken as a result of drug ineffective, covid-19.  No follow-up attempts are possible. No further information is expected.; Sender's Comments: Based on the information given in narrative, the causal relationship between the reported events  drug ineffective/COVID 19 and the suspect drug BNT162B2 cannot be excluded.
Initial report received from a health care professional in the USA on 10-August-2005. A 4 year old child became inconsolable, "wired," had a stuffy nose and his left arm was red at the injection site on the evening of the day he received Daptacel, lot number C220AA in the left deltoid. Patient received concomitant IPOL lot number 4032-5 in the left arm and MMR lot number 0150R in the right arm. Site and route of administration for vaccines was not reported. The patient has a history of mild asthma and allergies to Bactroban, penicillin and peanuts. He had no illness at the time of the vaccination. Concomitant drugs included Zovirax, Albuterol and Epipen. The patient's mother state the child appears to have less symptoms in the morning. There was no fever or hives reported. The mother phoned in the report and the child was not seen by a physician. Recovery status of the child was reported as unknown. Follow-up report received on 21-Sep-2005 from a health care professional. The onset date of the adverse events was confirmed as 08-Aug-2005. It was reported that the Daptacel was given intra-muscularly in the left arm and the IPOL subcutaneously in the left arm. The physician recommended the symptoms be treated with a steroid, and an allergist be contacted but the parent refused. The parent's primary concern during this adverse event was that the child was having a reaction to latex. The patient recovered from these events. No further information is expected.
10 days after vaccine depression loss of nervous system abilities. Loss of coordination and loss cloudy mental processes.
Patient received vaccine Monday morning and developed soreness to arm by afternoon with increased swelling and redness by Tuesday. Patient to office Wednesday morning. The follow up received on 11/11/03 states affected area of L arm was 4" x 3". he was treated successfully with Keflex, Advil and ice pack.
On day 6th after 1st dose of HPV and Influenza vaccine given at health center, forearms, hands, palms maculopapular erythematous rash that became heavy and spread to entire body. Patient had been seen by 2 dermatologist, patches/hives last for 1 1/2 weeks. Required treatment with oral steroids (Medrol pack). No other current illness such as fever, headache, arthralgia, arthritis or myalgia. Reaction developed despite oral Claritin daily.
Injection site became hot and extremely itchy, red mark about 1.5 inch diameter, lasted approximately 5 days and stopped. did not seek medical attention or take any medication (ibuprophin for unrelated joint pain)
bloody diarrhea; lightheadedness; vomiting; sweating; This is a spontaneous report from a contactable consumer (patient). A 44-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in arm right on 14Apr2021 at 15:30 (Lot Number: EW0161) (at the age of 44-year-old) as single dose for COVID-19 immunisation.  The patient was not pregnant. Medical history included migraine, thyroid cancer and fruit allergy (kiwi fruit), all from an unknown date and unknown if ongoing. Concomitant medication included gabapentin; gabapentin (NEURONTIN); venlafaxine hydrochloride (EFFEXOR); levothyroxine sodium (SYNTHROID); eletriptan hydrobromide (RELPAX), all concomitants were taken for an unspecified indication, start and stop date were not reported. On 17Apr2021 at 10:00, the patient experienced bloody diarrhea, lightheadedness, vomiting and sweating. No therapeutic measures were taken as a result of the events. The patient outcome of the events was unknown.
This spontaneous report was received from a female nurse of unknown age via company representative regarding herself (the nurse). The patient's concurrent condition, medical history, past drug, drug allergies and concomitant medications were not reported. On an unknown date, the patient was vaccinated with 3 dose series of RECOMBIVAX HB (route and dose unknown) (expiration date and lot number not specified) as prophylaxis. It was not specified if it was RECOMBIVAX HB vaccine. On an unknown date, after the patient received 3 dose series, titers were not showing that she converted (hepatitis B surface antibody negative). The patient had the 3-dose series again and still did not show that she registered on titer check. The patient sought medical attention with a doctor visit. The patient received unspecified treatment for the event and there was no intervention to prevent serious criteria. The patient did not have significant disability or incapacity and hospitalization and event was not life threatening. The outcome of the event hepatitis B surface antibody negative was reported as recovered/resolved on an unknown date. The reporter did not assess the causality of the event with suspect therapy. Product quality complaint was not involved.
Patient had a positive COVID test on 8/8/21; seen in the ED with weakness, fatigue, malaise; elevated troponins and hypokalemia; experienced SVT several times; cardiology consulted - ACS protocol (Acute coronary syndrome) and medication; O2 supplementation; ICU; DC'd from hospital on 8/13/21; Patient passed away in a park with COD being Complication of HTN and atherosclerotic cardiovascular disease; contributing conditions listed as COVID 19 and chronic alcoholism
myositis -- dermatomyositis; severe muscles pain and weakness, CK >1000
soar in left arm where shot was given about 12 hours later. soar skin, like a brush burn, on left arm by 5pm the next time. achiness, exhaustion by 7pm the next day.
Left deltoid tender; Left armpit is swollen and painful; Left armpit is swollen and painful; Left arm is red, warm and raised surrounding injection site (approx 2-3 inch diameter).; Left arm is red, warm and raised surrounding injection site (approx 2-3 inch diameter).; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 37 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 11Oct2021 15:45 (Lot number: FF2500) at the age of 37 years as dose 3 (booster), single for covid-19 immunisation; influenza vaccine (FLU), administered in arm left, administration date 11Oct2021 (Batch/Lot number: unknown) as dose 1, single for immunisation. The patient's relevant medical history was not reported. The patient took concomitant medications. Vaccination history included: Bnt162b2 (prev dose product=COVID 19, prev dose brand=Pfizer, prev dose brand unknown=False, prev dose lot number=EK9231, prev dose lot unknown=False, prev dose administration date=30Dec2020, prev dose dose number=1, prev dose vaccine location=Left arm), administration date: 30Dec2020, when the patient was 37 years old, for Covid-19 immunization; Bnt162b2 (prev dose product=COVID 19, prev dose brand=Pfizer, prev dose brand unknown=False, prev dose lot number= EL9261, prev dose lot unknown=False, prev dose administration date=19Jan2021, prev dose dose number=2, prev dose vaccine location=Left arm), administration date: 19Jan2021, when the patient was 37 years old, for Covid-19 immunization. The following information was reported: VACCINATION SITE NODULE (non-serious) with onset 12Oct2021, outcome "recovering", described as "Left deltoid tender"; SWELLING (non-serious), LYMPH NODE PAIN (non-serious) all with onset 12Oct2021, outcome "not recovered" and all described as "Left armpit is swollen and painful"; VACCINATION SITE ERYTHEMA (non-serious), VACCINATION SITE WARMTH (non-serious) all with onset 12Oct2021, outcome "not recovered" and all described as "Left arm is red, warm and raised surrounding injection site (approx 2-3 inch diameter).". Therapeutic measures were not taken as a result of vaccination site nodule, swelling, lymph node pain, vaccination site erythema, vaccination site warmth.  Additional information: Patient received other medications in two weeks. No other vaccine in four weeks, no Covid prior vaccination, no Covid tested post vaccination and had no known allergies. The arm/armpit area symptoms began about 12-18 hours after injection and have increased in severity since onset.  Follow-up attempts are completed. No further information is expected.
Sore arm started ~2hrs post-injection of dose 1. Fatigue set in ~4hrs post-injection and lasted 8hrs. Strong headache started ~12hrs post-injection and dulled/became achy until ending 36hrs post-injection. No symptoms since 1.5 days post-injection.